Results
|
1.
|
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. MedStar authors:
Year: 2021
Citation: - JCO Precision Oncology. 5, 2021.
Institution: - MedStar Union Memorial Hospital
Department: - Internal Medicine Residency
Medline publication type:
All authors: - Adra N, Agarwal N, Aggarwal R, Albany C, Alva AS, Antonarakis ES, Ashkar R, Barata P, Bastos D, Berchuck JE, Bryce A, Cheng HH, Fu W, Holler AE, Kessel A, Marshall CH, Nafissi N, Sartor AO, Smaletz O, Sokolova AO, Sternberg CN, Su C, Taplin ME, Taza F, Vlachostergios PJ, Wang H
|
|
2.
|
|
|
3.
|
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(33):3753-61, 2014 Nov 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Kiermaier A, Ross G, Swain SM
|
|
4.
|
|
|
5.
|
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. MedStar authors:
Year: 2017
Citation:
- JAMA Oncology. , 2017 Feb 09
- JAMA Oncology. 3(7):944-952, 2017 Jul 01
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Baker LH, Benjamin RS, Blackstein ME, Blanke CD, Borden EC, Corless CL, Crowley JJ, Demetri GD, Fletcher JA, Heinrich M, Maki RG, Owzar K, Priebat DA, Rankin C, Ryan CW, Tap WD, von Mehren M
|